INVL Private Equity Fund II, alongside IFC and ACP, has invested in Poland's POLMED to enhance healthcare services, particularly in oncology.

Information on the Target

POLMED, established in 1999, is one of the leading private healthcare service providers in Poland, with revenues exceeding €100 million in 2024. The company offers a wide range of services, including outpatient care, diagnostic imaging, inpatient services, and home rehabilitation. Operating 38 facilities and employing approximately 2,000 staff, POLMED collaborates with over 4,000 medical partners across Poland, serving more than 4 million patients annually and providing services to over 3,500 companies.

The acquisition targets the KN Group, comprising the Radom Oncology Center, the Gamma Knife Centre, and the Radom Family Centre, which has been operational since 2011. This prominent private oncology center includes three facilities in Radom and Warsaw, employing over 700 staff and providing approximately 150 beds, including 14 chemotherapy chairs. The group is led by internationally recognized neurosurgeon Prof. Mirosław Ząbek and Vice President Dorota Ząbek, both of whom will continuing their roles post-acquisition.

Industry Overview in Poland

The Polish healthcare industry has experienced significant growth in recent years, driven by increasing demand for healthcare services and the need for modernization. As the population ages and health awareness rises, there is a pre